Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 28, 2021; 27(32): 5424-5437
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5424
Table 2 Prevalence of adverse events after beginning sorafenib, according to CTCAE version 5.0, n (%)
| Group A (n = 41) | Group B (n = 30) | Group C (n = 63) | ||||||||||
| All grades | Grade 1 | Grade 2 | Grade 3 | All grades | Grade 1 | Grade 2 | Grade 3 | All grades | Grade 1 | Grade 2 | Grade 3 | |
| Any adverse event | 37 (90.2) | 30 (73.2) | 18 (43.9) | 5 (12.2) | 30 (100) | 28 (93.3) | 24 (80.0) | 14 (46.6) | 63 (100) | 58 (92.1) | 36 (57.1) | 14 (22.2) |
| Hand-foot skin reaction | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 30 (100) | 15 (50.0) | 10 (33.3) | 5 (16.7) | 63 (100) | 39 (61.9) | 19 (30.2) | 5 (7.9) |
| Anemia | 17 (41.5) | 8 (19.5) | 8 (19.5) | 1 (2.4) | 20 (66.6) | 13 (43.3) | 4 (13.3) | 3 (10.0) | 23 (36.5) | 14 (22.2) | 7 (11.1) | 2 (3.2) |
| Diarrhea | 15 (36.6) | 12 (29.3) | 3 (7.3) | 0 (0) | 11 (36.6) | 9 (30.0) | 1 (3.3) | 1 (3.3) | 27 (42.8) | 21 (33.3) | 2 (3.2) | 4 (6.3) |
| Fatigue | 14 (34.1) | 10 (26.8) | 3 (7.3) | 0 (0) | 11 (36.6) | 7 (23.3) | 4 (13.3) | 0 (0) | 16 (25.4) | 10 (15.9) | 6 (9.5) | 0 (0) |
| Anorexia | 14 (34.1) | 10 (24.4) | 3 (7.3) | 1 (2.4) | 7 (23.3) | 5 (16.7) | 1 (3.3) | 1 (3.3) | 19 (30.1) | 15 (23.8) | 4 (6.3) | 0 (0) |
| Hypertension | 12 (29.3) | 10 (24.4) | 2 (4.9) | 0 (0) | 7 (23.3) | 2 (6.6) | 5 (16.7) | 0 (0) | 23 (36.5) | 16 (25.4) | 4 (6.3) | 3 (4.8) |
| Thrombocytopenia | 9 (22.0) | 2 (4.9) | 4 (9.7) | 3 (7.3) | 23 (76.7) | 10 (33.3) | 8 (26.7) | 5 (16.7) | 20 (31.7) | 10 (15.9) | 5 (7.9) | 5 (7.9) |
| Alopecia | 6 (14.6) | 4 (9.7) | 2 (4.9) | 0 (0) | 2 (6.6) | 2 (6.6) | 0 (0) | 0 (0) | 20 (31.7) | 19 (30.2) | 1 (1.6) | 0 (0) |
| Hepatic encephalopathy | 1 (2.4) | 0 (0) | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
- Citation: Ochi M, Kamoshida T, Araki M, Ikegami T. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. World J Gastroenterol 2021; 27(32): 5424-5437
- URL: https://www.wjgnet.com/1007-9327/full/v27/i32/5424.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i32.5424